# Polyhydramnios

> A condition of **excess amniotic fluid volume** (>2000 mL) during pregnancy.

- Diagnosed by:

  - **Amniotic Fluid Index (AFI)** > 24 cm
  - **Single Deepest Pocket** > 8 cm

<details>
<summary>Amniotic Fluid</summary>

> Amniotic fluid is a clear, slightly yellowish liquid that surrounds the fetus during pregnancy, contained in amniotic sac.

### Functions of Amniotic Fluid

- Protect
- Permit
- Prevent
- Promotes

### Volumes of Amniotic Fluid at Different Weeks (MCQs)

- Increases progressively
  - 10 weeks - 30 ml
  - 20 wks - 300 ml
  - 30 wks - 600 ml
  - 38 wks - 1000 ml
- Rapid fall from term
  - 40 wks - 800 ml
  - 42 wks - 350 ml

</details>

## Classification

### By Severity:

| Severity | AFI        | SDP        |
| -------- | ---------- | ---------- |
| Mild     | 25–29.9 cm | 8–9.9 cm   |
| Moderate | 30–34.9 cm | 10–11.9 cm |
| Severe   | ≥35 cm     | ≥12 cm     |

### By Onset:

- **Acute** – rapid accumulation (often in 2nd trimester)
- **Chronic** – gradual increase (most common)

## Causes

> MOTHER’S FLUID

1. Multiple pregnancy

   - Especially with **twin-to-twin transfusion syndrome (TTTS)**

2. Obstruction of fetal swallowing

   - e.g., **Esophageal/duodenal atresia**, anencephaly

3. Twin-to-twin transfusion (TTTS)

   - Donor twin oligohydramnios, recipient twin polyhydramnios

4. Hydrops fetalis

   - Immune (Rh isoimmunisation) or non-immune

5. Endocrine (Maternal diabetes)

   - Hyperglycemia → fetal polyuria → ↑ AF volume

6. Renal disorders (fetal)

   - Increased urine output or decreased resorption

7. Skeletal dysplasia

   - Abnormal fetal movement → swallowing impairment

8. Fetal infections (TORCH)

   - e.g., Parvovirus B19, CMV → anemia, hydrops

9. Laryngeal/tracheal obstruction

   - Impairs swallowing

10. Unexplained (Idiopathic)

    - \~60% cases have no identified cause

11. Isoimmunisation (Rh)

    - Fetal anemia → hydrops → polyhydramnios

12. Down syndrome and other aneuploidies

    - Neuromuscular defects → swallowing issues

## Complications

### Maternal Complications:

1. **Preterm labour**

   - Overdistended uterus → irritability

2. **Abdominal discomfort / breathlessness**

   - Due to uterine size and diaphragmatic elevation

3. **Malpresentation**

   - Excess fluid → fetal mobility → breech or transverse lie

4. **Preterm premature rupture of membranes (PPROM)**

   - Increased pressure on membranes

5. **Placental abruption**

   - Sudden decompression after ROM

6. **Postpartum hemorrhage (PPH)**

   - Uterine atony from overstretching

### Fetal Complications:

1. **Congenital anomalies**

   - Especially GI and CNS (e.g., anencephaly, atresias)

2. **Umbilical cord prolapse**

   - When presenting part is unengaged

3. **Fetal distress**

   - Due to cord compression or malpresentation

4. **Intrauterine fetal death (IUFD)**

   - Especially if associated with hydrops or anomalies

5. **Macrosomia** (if maternal diabetes is the cause)

### Postnatal Complications:

1. **Neonatal respiratory distress**

   - From prematurity or aspiration

2. **Feeding difficulties**

   - In cases with GI malformations

## Diangosis

### Clinical Evaluation:

- Abdominal distension, dyspnoea, edema
- Difficulty palpating fetal parts
- Uterus larger than gestational age

### Confirm with Ultrasound:

- **AFI measurement**
- **Detailed anomaly scan** – rule out:

  - Anencephaly
  - Duodenal atresia
  - Oesophageal atresia
  - Twin-to-twin transfusion (in monochorionic twins)

### Baseline Investigations:

- **OGTT / FBS** – rule out gestational diabetes
- **TORCH screen** – for CMV, toxoplasmosis, syphilis
- **Karyotyping** (amniocentesis) – if structural anomaly found
- **Fetal echocardiography** – if fetal hydrops or arrhythmias
- **Anti-Rh antibodies** if Rh-negative mother

## Management

### I. Pre-Conception Management

- **Glycaemic control** in diabetics
- **Genetic counselling** in patients with previous congenital anomalies
- **Folic acid** 5 mg/day to reduce neural tube defects

### II. Antenatal Management

#### Mild Polyhydramnios

**(AFI 25–29.9 cm, asymptomatic)**

- **Outpatient monitoring**

  - Repeat **USG every 2–3 weeks**
  - Monitor **fundal height and maternal symptoms**

- **Fetal surveillance**

  - **CTG weekly** after 32 weeks
  - Growth scans every 2–4 weeks

#### Moderate to Severe / Symptomatic

##### 1. Medical Therapy (Before 32 Weeks)

- `Indomethacin` (Prostaglandin synthetase inhibitor)

  - ↓ Fetal urine production → ↓ AF volume
  - **Dose**:

    - **25 mg PO every 6 hours**, max 150 mg/day
    - Duration: 48–72 hrs, reassess

  - **Monitor**:

    - Ductus arteriosus (via fetal echo)
    - Oligohydramnios

  - ~~Contraindications~~:

    - \> 32 weeks GA (risk of ductal closure, neonatal renal dysfunction)
    - Asthma, peptic ulcer

##### 2. Therapeutic Amnioreduction

- **For severe maternal discomfort or compromised respiration**
- Under USG guidance:

  - Remove \~500–1500 mL gradually
  - May repeat weekly

- Risks:

  - Preterm labour, abruption, infection

##### 3. Treat Underlying Cause

- **Diabetes** → Control blood glucose
- **Infections** → Treat TORCH infections if proven
- **Fetal anomaly** → Counselling, preparation for neonatal support

## III. Intrapartum Management

### Admission Criteria:

- Severe polyhydramnios
- Symptomatic (e.g. dyspnoea, pressure symptoms)
- Evidence of preterm labour or fetal compromise

### Delivery Planning:

#### a. Time:

- **Mild, no complications** → Deliver at term (39–40 weeks)
- **Severe/symptomatic** → Elective delivery at **37–38 weeks**
- **Preterm delivery** if:

  - Uncontrolled symptoms
  - Fetal compromise
  - Preterm labour

#### b. Mode:

- **Vaginal delivery** if no obstetric contraindication
- **CS** if:

  - Fetal malpresentation
  - Anomaly incompatible with vaginal birth
  - Previous uterine surgery
  - Non-reassuring fetal status

#### c. Special Considerations:

- **Cautious ARM (Artificial Rupture of Membranes)**:

  - High risk of **cord prolapse**, **placental abruption**

- Continuous **CTG monitoring**
- Prepare for:

  - **PPH** (overdistended uterus)
  - **Neonatal resuscitation**

## IV. Postpartum Care

### Maternal Monitoring:

- Watch for **PPH**, **uterine atony**
- Oxytocics:

  - **Oxytocin 10 IU IM** after delivery
  - **IV oxytocin infusion 10–40 IU in 500 mL NS/RL**

- Monitor Hb and vitals
- Evaluate for retained placenta

### Neonatal Evaluation:

- Structural anomalies
- Chromosomal syndromes (e.g., Trisomy 18)
- Respiratory issues (e.g., from prematurity)

## V. Contraception

### Preferred Options

| Method                            | Reason                                               |
| --------------------------------- | ---------------------------------------------------- |
| **DMPA 150 mg IM every 3 months** | Safe, long-acting, reversible                        |
| **Progesterone implant**          | Effective, avoids uterine complications              |
| **POP (desogestrel 75 mcg)**      | Safe if breastfeeding                                |
| **LNG-IUS / Copper IUD**          | Insert after 6 weeks if uterus involuted             |
| **Tubal ligation**                | If family is complete, especially if anomaly present |

### Avoid:

- COC in early postpartum (↑ VTE risk)
- IUD insertion during puerperium with uterine atony/infection

## Follow-Up

- Counsel for future pregnancy risks
- Recurrence is rare unless persistent cause (e.g., DM, anomaly)
- Pre-conception screening in next pregnancy

## Key Points Summary

| Aspect          | Action                               |
| --------------- | ------------------------------------ |
| Diagnosis       | USG → AFI >25 cm / DVP >8 cm         |
| Investigations  | OGTT, TORCH, anomaly scan, karyotype |
| Medical Tx      | Indomethacin (before 32 wks)         |
| Symptomatic Rx  | Amnioreduction                       |
| Delivery timing | 37–38 weeks if severe                |
| ARM caution     | Cord prolapse, abruption risk        |
| Postpartum care | PPH risk ↑; neonatal exam            |
| Contraception   | Progestin-based / permanent          |
